top of page

Canurta Launches Satoshi Trials, Advances CNR-401, and Expands Public Market Strategy

ree

PHRX LOI Signed: Strategic Path to the Public Markets


Canurta Therapeutics has signed a Letter of Intent with PharmaDrug Inc. (CSE: PHRX.CN), outlining the terms for a proposed acquisition of up to 40 percent of Canurta. The first tranche of the transaction is expected to close within Q3 2025, pending customary due diligence and regulatory approval. This agreement represents a key milestone in our strategy to access public markets and follows our recent LOI with extractX Ltd.


Together, these partnerships are designed to unlock growth capital, enhance operational scale, and support the advancement of our clinical pipeline, including CNR-401 and the Satoshi Trials. As part of the agreement, Canurta CEO Akeem Gardner will be appointed to PharmaDrug’s Board of Directors.



Satoshi Trials: Treasury Innovation Through Bitcoin


We have formally launched the Satoshi Trials, a strategic initiative to integrate Bitcoin into Canurta’s treasury and performance frameworks. Going forward, key indicators such as Bitcoin-denominated net asset value, yield per unit, collateralization ratio, and accretion rate will be reported alongside traditional financial metrics.


This move reinforces our commitment to capital preservation, transparency, and long-term value creation in both fiat and Bitcoin terms. The Satoshi Trials mark a foundational shift in how we measure performance and align our corporate strategy with sound money principles.



Preclinical Milestone for CNR-401


Canurta’s R&D team has completed a preclinical study evaluating the ability of CNR-401 to cross the blood-brain barrier in mice. The results confirmed that key cannabinoids and select terpenes reached both brain tissue and cerebrospinal fluid, reinforcing the compound’s potential for central nervous system applications.

These findings represent a meaningful step in the development of CNR-401 as a candidate for neuroinflammatory and neurodegenerative conditions.


Advancing Automation in Drug Discovery


Canurta continues to implement key upgrades to our Polykye™ discovery infrastructure. Our bioinformatics team has rolled out autonomous AI agent assistants capable of independently proposing, testing, and refining flavonoid candidates. Alongside this, we’ve deployed a proteome-wide screening engine that evaluates novel compounds against thousands of human proteins, surfacing high-probability targets while flagging potential off-target effects early.


Together, these systems are accelerating the path from molecular concept to ranked candidate shortlists with greater speed, accuracy, and consistency.


ree

CEO Insight: CanadianSME Podcast Feature


Canurta CEO Akeem Gardner recently joined Kripa Anand on the CanadianSME Small Business Podcast to discuss the evolving role of Bitcoin in strengthening capital strategies for Canadian biotech. The conversation addressed the persistent underfunding of pre-clinical research in Canada and explored how Bitcoin can serve as a financial infrastructure tool for long-term resilience.


Gardner also outlined practical steps for research-intensive SMEs interested in modernizing their approach to treasury management. This interview offers timely insight into the financial philosophy behind Canurta’s approach to innovation and sustainability.



ree

Event Recap: Black Blockchain Summit


In September, Akeem Gardner participated in the 8th Annual Black Blockchain Summit at Howard University, joining conversations on infrastructure ownership and the role of Bitcoin in Black communities. These sessions brought together leaders from blockchain, Web3, and Black tech sectors to explore how decentralized tools can support economic sovereignty and community resilience.


Gardner’s involvement underscores Canurta’s commitment to shaping the future of financial and scientific innovation through active participation in cross-sector dialogue. Highlights from the summit will be shared once available.


bottom of page